News · 26 weeks540%
2026-04-192026-10-11
Mix2190d
- Other8(38%)
- SEC Filings5(24%)
- Earnings2(10%)
- Analyst2(10%)
- Leadership2(10%)
- Insider2(10%)
Latest news
25 items- PREnrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold102 patients enrolled across 14 European centers to assess safety and clinical performance of 35 mm and 40 mm Freesolve™ Resorbable Magnesium Scaffolds in long coronary lesions Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the successful completion of patient enrollment in the BIOMAG™-LL Clinical Study, evaluating the safety and clinical performance of the Freesolve™ Resorbable Magnesium Scaffold (RMS) in 35 mm and 40 mm lengths for the treatment of de novo coronary lesions up to 38 mm. The study reflects Teleflex's commitment to expanding clinical evidence supporting the use of the Freesolve™ RMS in percutaneous coronary intervention
- PRTeleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ TechnologyPeer-reviewed publication in the American Journal of Infection Control demonstrates the use of CVCs protected with Arrowg+ard™ Technology are associated with a statistically significant and clinically meaningful reduction in the hazard of CLABSI compared with plain CVCs1. Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters (CVCs) protected with Arrowg+ard™ Technology were associated with a statistically significant 70% lower hazard of central line-associated bloodstream infections (CLABSIs) compared with
- PRNyxoah Appoints Liam Kelly as Chief Executive OfficerREGULATED INFORMATIONINSIDE INFORMATION Nyxoah Appoints Liam Kelly as Chief Executive Officer Further strengthening the Company’s strategic U.S. presence and focus Mont-Saint-Guibert, Belgium – September 28, 2026, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding Olivier Taelman. The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA appr
- ANALYSTTeleflex upgraded by BofA Securities with a new price targetBofA Securities upgraded Teleflex from Neutral to Buy and set a new price target of $158.00
- INSIDERDirector Salmon Sean was granted 674 shares (SEC Form 4)4 - TELEFLEX INC (0000096943) (Issuer)
- INSIDERSEC Form 3 filed by new insider Salmon Sean3 - TELEFLEX INC (0000096943) (Issuer)
- PRTeleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of DirectorsTeleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026. Mr. Salmon brings over three decades of global leadership experience in the medical device and pharmaceutical industries, culminating in more than 20 years at Medtronic plc (NYSE:MDT). He most recently served as Executive Vice President and President of its Cardiovascular Portfolio, a global business with fiscal 2025 revenue of approximately $12.5 billion for which Mr. Salmon was instrumental in developing the growth strategy. He previously held leadership roles across Medtronic’s Diabetes, Coronary a
- PRTeleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026Results from previously presented BIONETIC-TRA study demonstrate the safety and feasibility of the device via trans-radial approach Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technologies will be the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System. This technology is supported by the previously presented BIONETIC-TRA study, an investigator-initiated study with a 30-day follow-up period, that evaluated the safety and feasibility of the Dynetic™-35 Balloon-Ex
- SECTeleflex Incorporated filed SEC Form 8-K: Other Events8-K - TELEFLEX INC (0000096943) (Filer)
- SECSEC Form 10-Q filed by Teleflex Incorporated10-Q - TELEFLEX INC (0000096943) (Filer)
- SECTeleflex Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TELEFLEX INC (0000096943) (Filer)
- PRTeleflex Announces Quarterly DividendTeleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 30, 2026, to shareholders of record at the close of business on August 14, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. W
- PRTeleflex Reports Second Quarter Financial Results and Full Year 2026 OutlookCompletes Sale of OEM Business and Will Deploy Net Proceeds to Reduce Debt and Repurchase Common Stock Announces $250 Million Accelerated Share Repurchase Program, Repurchased $250 Million of Common Stock in the Second Quarter Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the second quarter ended June 30, 2026. Second quarter 2026 continuing operations financial summary1 Revenue from continuing operations of $570.3 million, up 28.9% compared to the prior year period, and up 4.7% on a pro forma adjusted constant currency basis1,2 GAAP diluted EPS from continuing operations of $0.96, compared to $1.54 in the prior year period Adjusted di
- SECAmendment: Teleflex Incorporated filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - TELEFLEX INC (0000096943) (Filer)
- PRTeleflex Medical OEM Launches as INGENYX to Empower Tomorrow’s MedTech InnovatorsCombining leading in-house expertise with platform-enhancing investments to accelerate advances in engineering, innovation and manufacturing capabilities serving global medical device innovators Marks completion of acquisition by Montagu and Kohlberg PLYMOUTH, Minn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- INGENYX, formerly Teleflex Medical OEM, today announced its launch as an independent company following the completion of its acquisition by Montagu and Kohlberg and carve-out from Teleflex Incorporated (NYSE:TFX). The transaction was first announced on December 9, 2025. Rooted in more than 40 years of experience serving medical device manufacturers, INGENYX develops and manufactures custom-
- SECTeleflex Incorporated filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure8-K - TELEFLEX INC (0000096943) (Filer)
- PRTeleflex Completes Strategic Divestiture of OEM Business for $1.5 BillionIntends To Utilize Net Proceeds To Pay Down Debt and Repurchase Shares Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it has completed the previously disclosed divestiture of its OEM business to Montagu and Kohlberg, for $1.5 billion in cash. The close of the OEM transaction marks a pivotal milestone in Teleflex's transformation strategy, sharpening the Company's focus on the commercial excellence of its continuing businesses. The divestiture strengthens Teleflex's financial flexibility and positions it to accelerate innovation and drive sustainable, profitable growth while returning significant capital to shareholders. Further, it
- PRTeleflex Announces FDA BLA Approval of EZPLAZ™ Freeze Dried PlasmaFirst and only FDA-Approved Freeze Dried Plasma Product Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it has received Biologics License Application (BLA) approval for EZPLAZ™ Freeze Dried Plasma (FDP) from the U.S. Food and Drug Administration (FDA). EZPLAZ™ FDP is approved for transfusion in adults with bleeding-related conditions requiring replacement of plasma coagulation factors, including uncontrolled bleeding (hemorrhage), when plasma is required and other plasma products are not available. This landmark approval is the first freeze dried plasma licensed by the FDA, and the first biologics license for a blood component for Telef
- ANALYSTUBS initiated coverage on Teleflex with a new price targetUBS initiated coverage of Teleflex with a rating of Neutral and set a new price target of $145.00
- PRTeleflex Announces Second Quarter 2026 Earnings Conference Call InformationTeleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 6, 2026. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, teleflex.com. An audio replay of the call will be available beginning at 11:00 am Eastern Time on August 6, 2026, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conference ID is 69
- PRTeleflex Awarded National Central Venous Access Agreement with Premier, Inc.Teleflex Incorporated (NYSE:TFX) has been awarded a national group purchasing agreement for central venous access products with Premier, Inc. Effective July 1, 2026, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for select Teleflex products, including short-term central venous catheters, arterial catheter products, and intraosseous vascular access solutions. "As healthcare systems continue to focus on patient safety, standardization, and operational efficiency, we are proud to expand access to Teleflex’s vascular access portfolio through this agreement with Premier," said Cris Gomide, Vice President
- ANALYSTBMO Capital Markets initiated coverage on Teleflex with a new price targetBMO Capital Markets initiated coverage of Teleflex with a rating of Outperform and set a new price target of $159.00
- SECSEC Form 11-K filed by Teleflex Incorporated11-K - TELEFLEX INC (0000096943) (Filer)
- PRTeleflex Initiates Enrollment in Global BIOMAG™‑III Pivotal Trial of Freesolve™ Resorbable Magnesium ScaffoldEnrollment completed ahead of schedule in BIOMAG™-II Positive four-year BIOMAG™-I results recently reported Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the beginning of enrollment in the BIOMAG™‑III Study (NCT07258290), a landmark global study evaluating the Freesolve™ Resorbable Magnesium Scaffold (RMS). Dr. Itsik Ben-Dor, MedStar Health in Washington, D.C., is the first implanter in the United States (U.S.) in the IDE trial of Freesolve™ RMS. Designed as a pivotal trial to support future regulatory applications, the BIOMAG™‑III Study represents the most comprehensive planned clinical evaluation of Freesolve™ RMS to date. Cha
- SECTeleflex Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - TELEFLEX INC (0000096943) (Filer)
TFX FAQ
7 questionsWhat does Teleflex Incorporated do?
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary...Where does TFX stock trade?
Teleflex Incorporated (TFX) is listed on NYSE.What sector and industry is TFX in?
Teleflex Incorporated operates in the Health Care sector, Medical/Dental Instruments industry.Does TFX pay a dividend?
TFX's most recent ex-dividend date was 2026-08-14 with a cash dividend of $0.34 per share. No future ex-date is on file yet.What are analysts saying about TFX?
Teleflex Incorporated has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy on 2026-09-28.What companies are similar to TFX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare TFX side-by-side with any of them on Quantisnow.How can I track TFX on Quantisnow?
Quantisnow aggregates Teleflex Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TFX to receive live email and push alerts on every new disclosure.